Case studies with the experts: Management decisions in atrial fibrillation

Journal of Cardiovascular Electrophysiology

Volumn 19, Issue SUPPL. 1, 2008, Pages

  Prystowsky, Eric N ^a   JaÏs, Pierre ^b   Kowey, Peter ^c   Nattel, Stanley ^d   Ruskin, Jeremy N ^e  

^a Care Group   (United States)

^b HAUT LÉVÊQUE HOSPITAL   (France)

^c Main Line Health Heart Center   (United States)

^d MONTREAL HEART INSTITUTE   (Canada)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antiarrhythmic drugs; Anticoagulation; Atrial fibrillation; Cardioversion; Catheter ablation

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; CALCIUM CHANNEL; CLOPIDOGREL; IRBESARTAN; VALSARTAN; WARFARIN;

ADD ON THERAPY; ADULT; ANAMNESIS; ANTICOAGULANT THERAPY; CASE REPORT; CLINICAL PRACTICE; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; ECHOCARDIOGRAPHY; FEMALE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE HYPERTROPHY; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LONG TERM CARE; MALE; MONOTHERAPY; OUTPATIENT CARE; PATIENT CARE; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PREVENTION AND CONTROL; PRIORITY JOURNAL; STROKE; SYMPTOMATOLOGY; TRANSIENT ISCHEMIC ATTACK;

ADOLESCENT; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CATHETER ABLATION; DISEASE MANAGEMENT; FEMALE; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL; UNITED STATES;

EID: 38549145394     PISSN: 10453873     EISSN: 15408167     Source Type: Journal    
DOI: 10.1111/j.1540-8167.2007.01053.x     Document Type: Conference Paper

References (24)

1. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TS : Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006 114 : 119 125.
2. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA : Independent risk factors for atrial fibrillation in a population-based cohort: The Framingham Heart Study. JAMA 1994 271 : 840 844 (B).
3. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG : Prevalence, age distribution, and gender of patients with atrial fibrillation: Analysis and implications. Arch Intern Med 1995 155 : 469 473 (B).
4. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S Task Force on Practice Guidelines, American College of Cardiology/American Heart Association; Committee for Practice Guidelines, European Society of Cardiology; European Heart Rhythm Association; Heart Rhythm Society : ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation - executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J 2006 27 : 1979 2030 (A).
5. Fuster V, Rydén LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Lévy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Russell RO, Smith SC, Klein WW, Alonso-Garcia A, Blomström-Lundqvist C, De Backer G, Flather M, Hradec J, Oto A, Parkhomenko A, Silber S, Torbicki A American College of Cardiology/American Heart Association/European Society of Cardiology Board : ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001 38 : 1231 1266 (A).
6. Rockson SG, Albers GW : Comparing the guidelines: Anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation. J Am Coll Cardiol 2004 43 : 929 935 (A).
7. Muszkat M, Blotnik S, Elami A, Krasilnikov I, Caraco Y : Warfarin metabolism and anticoagulant effect: A prospective, observational study of the impact of CYP2C9 genetic polymorphism in the presence of drug-disease and drug-drug interactions. Clin Ther 2007 29 : 427 437 (B).
8. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators : A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002 347 : 1825 1833 (A).
9. Li D, Fareh S, Leung TK, Nattel S : Promotion of atrial fibrillation by heart failure in dogs: Atrial remodeling of a different sort. Circulation 1999 100 : 87 95.
10. Pan CH, Lin JL, Lai LP, Chen CL, Stephen Huang SK, Lin CS : Downregulation of angiotensin converting enzyme II is associated with pacing-induced sustained atrial fibrillation. FEBS Lett 2007 581 : 526 534.
11. Feng J, Wible B, Li GR, Wang Z, Nattel S : Antisense oligodeoxynucleotides directed against Kv1.5 mRNA specifically inhibit ultrarapid delayed rectifier K+ current in cultured adult human atrial myocytes. Circ Res 1997 80 : 572 579.
12. Ausma J, van der Velden HM, Lenders MH, van Ankeren EP, Jongsma HJ, Ramaekers FC, Borgers M, Allessie MA : Reverse structural and gap-junctional remodeling after prolonged atrial fibrillation in the goat. Circulation 2003 107 : 2051 2058.
13. Hsu LF, Jaïs P, Sanders P, Garrigue S, Hocini M, Sacher F, Takahashi Y, Rotter M, Pasquié JL, Scavée C, Bordachar P, Clémenty J, Haïssaguerre M : Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 2004 351 : 2373 2383 (B).
14. Corley SD, Epstein AE, DiMarco JP, Domanski MJ, Geller N, Greene HL, Josephson RA, Kellen JC, Klein RC, Krahn AD, Mickel M, Mitchell LB, Nelson JD, Rosenberg Y, Schron E, Shemanski L, Waldo AL, Wyse DG AFFIRM Investigators : Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 2004 109 : 1509 1513 (A).
15. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM Valsartan in Acute Myocardial Infarction Trial Investigators : Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003 349 : 1893 1906 (A).
16. Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, Michelson EL, McMurray JJ, Olsson L, Rouleau JL, Young JB, Olofsson B, Puu M, Yusuf S CHARM Investigators : Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006 152 : 86 92 (A).
17. Madrid AH, Bueno MG, Rebollo JM, Marín I, Peña G, Bernal E, Rodriguez A, Cano L, Cano JM, Cabeza P, Moro C : Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: A prospective and randomized study. Circulation 2002 106 : 331 336 (A).
18. The Active Steering Committee; ACTIVE Investigators, Connolly S, Yusuf S, Budaj A, Camm J, Chrolavicius S, Commerford PJ, Flather M, Fox KA, Hart R, Hohnloser S, Joyner C, Pfeffer M, Anand I, Arthur H, Avezum A, Bethala-Sithya M, Blumenthal M, Ceremuzynski L, De Caterina R, Diaz R, Flaker G, Frangin G, Franzosi MG, Gaudin C, Golitsyn S, Goldhaber S, Granger C, Halon D, Hermosillo A, Hunt D, Jansky P, Karatzas N, Keltai M, Lanas F, Lau CP, Le Heuzey JY, Lewis BS, Morais J, Morillo C, Oto A, Paolasso E, Peters RJ, Pfisterer M, Piegas L, Pipillis T, Proste C, Sitkei E, Swedberg K, Synhorst D, Talajic M, Trégou V, Valentin V, van Mieghem W, Weintraub W, Varigos J : Rationale and design of ACTIVE: The atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. Am Heart J 2006 151 : 1187 1193 (A).
19. Bode F, Sachs F, Franz MR : Tarantula peptide inhibits atrial fibrillation. Nature 2001 409 : 35 36.
20. Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, Radzik D, Aliot EM, Hohnloser SH EURIDIS and ADONIS Investigators : Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007 357 : 987 999 (A).
21. Touboul P, Brugada J, Capucci A, Crijns HJ, Edvardsson N, Hohnloser SH : Dronedarone for prevention of atrial fibrillation: A dose-ranging study. Eur Heart J 2003 24 : 1481 1487 (A).
22. Clinicaltrials.gov : ATHENA: A trial with dronedarone to prevent hospitalization or death in patients with atrial fibrillation. http://clinicaltrials.gov/ct/show/NCT00174785. Accessed September 25, 2007 (A).
23. Pratt C, Roy D, Juul-Moller S, Torp-Pedersen C, Toft E, Wyse DG, Nielsen T, Rasmussen SL, on behalf of the ACT III Investigators : Efficacy and tolerance of RSD1235 in the treatment of atrial fibrillation or atrial flutter: Results of a phase III, randomized, placebo-controlled, multicenter trial. J Am Coll Cardiol 2006 47 Suppl A : 10A (A).
24. Liu L, Nattel S : Differing sympathetic and vagal effects on atrial fibrillation in dogs: Role of refractoriness heterogeneity. Am J Physiol Heart Circ Physiol 1997 273 : H805 H816.